Our Surgical Oncology Forum entitled, “Advancing Knowledge in Multidisciplinary Lung Cancer Care” is partially supported by an educational grant from AstraZeneca.
AstraZeneca will be participating with a virtual exhibit as part of the enduring content.
At the forefront of lung cancer treatment.
We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
We are leading a revolution in oncology to redefine cancer care. Our portfolio of approved and potential new medicines in late-stage development spans different histologies, several stages of disease, lines of therapy and modes of action. Our approach is driven by precision medicine, using groundbreaking science to further our understanding of lung cancer and deliver medicines matched to the patients who can best benefit from them. This includes thinking differently about the underlying biology of lung cancer, from early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.